-
Most Recent
Search Results
240 results for MJN
Abbott Labs Spinoff Looks Like the Right Move
Shareholders would likely be better served by the company’s prescription drug business standing alone. Here’s why.
55 Trades to Make Before Earnings Season Ends
Earnings season continues, and I’ve provided you with my most recent grades on 55 stocks; take a look and trade accordingly
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market’s potential. Still, patent expirations loom large and won’t be easily overcome.
Mead Johnson Bounce Followed J&J Script
Mead Johnson’s recent Enfamil scare sent many investors packing — but those who stuck with the stock could soon be rewarded.
Is Pfizer Move to Sell Non-Pharma Divisions Bad Medicine?
Pfizer has said it will shed its nutritional and animal health businesses to pump more money into its drug pipeline. But is the move risky?
Pfizer Shares – 3 Pros, 3 Cons
Will a robust pipeline offset the loss of patent protection on key drugs?
Will Less Be More for Big Pharma?
Companies seem split on the asset selloff strategy.
The Dow Jones Transportation Average Is Showing Cracks
A breakdown isn’t imminent in the Dow Jones Transportation Average, but traders should keep a close eye on it.
Investing in Generation Y and the Next Great Baby Boom
Much like the Baby Boomers did more to shape the U.S. over the past 50 years, their children — Generation Y — will shape the…
52 Trades to Beat the Mutual Fund Slump
I’ve taken some of the guesswork out of stock picking for you by updating my ratings for these 52 stocks.
Mead Johnson Might Be One to Shed
Sales for Mead Johnson Nutrition’s baby food have been robust, but dividends and earnings growth have been mediocre.
IPOs Investing – Why You Want to Invest in IPOs NOW!
We are looking at the hottest IPO market we have seen in years, and you’ll be kicking yourself if you miss out.
50 Ways to Make Market Swings Work For You
With the stock market moving around in earnings season, now is the time to look through our buy and sell chart looking for ways to…
What To Make Of Tuesday’s Surprising Market Move
Wall Street clearly made up for the shortened trading week with a broad rally on Tuesday. Here’s our new research on 50 stocks in Portfolio…
4 Blue Chips Ripe for Spin-Offs
Spin offs from Motorola and Marathon hint at four other companies that may have spinoffs soon – Pfizer, Yahoo, Symantec and GE.
12 Companies Increasing Dividends
Colgate-Palmolive, General Dynamics, Qualcomm and Staples are among this week’s top payout performers.
47 Actions To Take On the Dow’s Big Dive
Earnings are the main driver of value in this market, and I’ve laid out my latest Portfolio Grader ratings for you to follow today….
Concerned About a Selloff? Here’s 68 Things You Can Do
Last week’s market drop caused concern among investors; there is no need to panic, and I’ll start you off with stocks to buy on the…
Steve Jobs Dreamed it. Elon Musk Is Making it Fruitful.
Steve Jobs dreamed of revitalizing American industry, and Elon Musk’s Optimus robot may finally turn that vision into reality – profitably.
It May Be Time to Trim Away at Your Portfolio
The stock market is doing well for October, but its may be time to look through your portfolio in order to trim away some of…
Start Browsing Consumer Staples Stocks for Fairly Priced Defense
The consumer staples sector has underperformed in 2014, bringing valuations down to more reasonable levels. The time to buy the sector is nearing, but…
An Early Review of InvestorPlace’s 2012 Picks
How are we doing so far this year? Several writers provide the answer: Sometimes right on the money. Sometimes not.
8 – 10 of 240 results
